Qian Panpan, Peng Chun Hong, Ye Xianwei
ZunYi Medical University, Zunyi, Guizhou Province, China.
Department of Respiration and Critical Care Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China.
Respir Med Case Rep. 2019 Jan 26;26:212-214. doi: 10.1016/j.rmcr.2019.01.014. eCollection 2019.
Recently, interstitial lung disease significantly increases and it is difficult to treat. Cyclophosphamide(CP) is one drug administrated in interstitial lung disease, which can also cause pulmonary fibrosis and lung function lesion. This article present a case which exacerbated interstitial pneumonia after treatment by CP, aiming to enhance the understanding of the side effects of CP and standardize usage of the CP.
A patient of nephrotic syndrome administrated with CP suffered respiratory insufficiency requiring mechanical ventilation. Computed tomography (CT) imaging was compatible with interstitial pneumonia(IP). After treating with multimodal combination therapy (corticosteroids, immune globulins), the patient survived. The clinical characteristics of CP-related lung toxicity and/or pulmonary fibrosis should be paid more attention to avoid the serious outcomes.
Although interstitial lung disease induced by CP is rare, with the current widespread usage of CP increases the risks of diffuse interstitial pneumonia and pulmonary fibrosis, which need to be noted in time to get early treatment.
近年来，间质性肺病显著增加且治疗困难。环磷酰胺（CP）是用于间质性肺病的一种药物，它也可导致肺纤维化和肺功能损害。本文介绍1例经CP治疗后加重间质性肺炎的病例，旨在提高对CP副作用的认识并规范CP的使用。
1例接受CP治疗的肾病综合征患者出现呼吸功能不全，需要机械通气。计算机断层扫描（CT）影像符合间质性肺炎（IP）表现。经多模式联合治疗（皮质类固醇、免疫球蛋白）后，患者存活。应更加关注CP相关肺毒性和/或肺纤维化的临床特征，以避免严重后果。
虽然CP所致间质性肺病罕见，但随着CP目前的广泛使用，弥漫性间质性肺炎和肺纤维化的风险增加，需要及时注意以便尽早治疗。
